Advisory Committees: US FDA Gets Out Of The Redaction Business

05 Feb 2017

Panel members’ curricula vitae will now be released without a review and redaction of potentially confidential information; FDA’s policy change is part of a settlement of lawsuit with Public Citizen.

The US FDA’s decision to stop redacting the curricula vitae (CV) of advisory committee members before public disclosure should increase transparency and save agency resources, but it also resolves a lawsuit brought by the Public Citizen Foundation.

In a notice that will appear in the Feb. 6 Federal Register, FDA said it will no longer...